CD47 and neoplasm: In the context of MSLN-targeted therapies, bsAbs have been engineered to simultaneously bind a tumor-associated antigen, such as MSLN, and a co-stimulatory receptor expressed on T-cells (e.g., CD3, CD20, CD47, CD137) [149].